Europe

f9a57bfe-51c7-11e9-8939-5623721d3707

Europe’s pragmatic approach to clinical evidence for legacy devices – or why the devil is always in the detail…

By Arthur Brandwood | 30 March, 2019
Regulatory affairs demand attention to detail. So when the European Medical Devices Coordination Group released document MDCG 2019-3 - Interpretation of Article 54(2)b we regulatory geeks just knew we should...
TrainXstation

Halfway there? Will the MDR/IVDR train arrive on time – and what about Brexit?

By Luis Jimenez | 3 December, 2018
As the implementation journey for the EU MDR/IVDR passes the halfway point, we provide an update to the current state of play and the impact on our industry. Many, if...

Search

Recent Posts

New Guidance on FDA ISO 10993-1

Sep 14, 2020

Australian Prescription Medicine Pathways – Project Orbis

Sep 1, 2020

TGA Advertisement Framework Revisions Hard at Work During Pandemic Times

Aug 31, 2020

Chemical Characterisation – no simple matter

Aug 28, 2020

Multiple Function Devices

Aug 26, 2020

Impact of COVID-19 on Medical Device Sales and Reimbursement in Australia

Aug 10, 2020

Categories

Categories

Archives

Archives

Archives

Tags

510(k) APAC Australia Biocompatibility Brexit CE CE Certificates clinical trials coronavirus COVID-19 COVID19 de novo distribution Drug EU Europe FDA guidance ISO 10993-18 IVD IVDD IVDR MDD MDR MDSAP medical device Medical Device Regulations medical devices Medicine medicines New Zealand Notified Bodies Pharmaceutical PMA PMDA postmarket private health insurance Quality Systems Reform regulatory Reimbursement SaMD Software standards TGA